Total Support for Biomarker Discovery
Supporting drug discovery & development for personalized medicine,
by providing project planning, IRB to data analysis services.
Drug Development
In Japan a PhaseI clinical trial of glufosfamide in patients with
solid tumors. (Glufosfamide is in PhaseIII in US targeting Pancreatic
Cancer,and in PhaseII for Ovarian Cancer,Lung Cancer and Soft
Tissue Sarcoma.)
We are making the best out of our geographical advantage, rich
experience of collaboration with Asian companies and the broad networks
that have been built through our past activities.
Our main targets are as follows:
Clients
Japanese pharmaceutical companies interested in PGx as well as overseas
companies, considering to collaborate with competitive biotechnology
companies in Asia.
Market
1. Researchers interested in Biomarker Discovery.
2. Competitive biotechnology companies in India, China, and Korea
that are eager to play roles in global collaboration and able to
offer their expertise for drug development R&D.
